UCB Soars Most Since 2009 After Winning Ruling on Epilepsy Drug

  • U.S. decision is ‘long-awaited sentiment boost,’ Citi says
  • Judge rules in favor of UCB over patent for drug Vimpat

UCB SA surged the most in more than seven years in Brussels trading after the Belgian drugmaker won a U.S. court ruling in a bid to block generic competition to one of its best-selling medicines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.